Results 91 to 100 of about 3,776 (143)

Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma

Journal for ImmunoTherapy of Cancer
Adult T-cell leukemia/lymphoma (ATLL), an aggressive T-cell malignancy associated with human T-cell leukemia virus type 1, presents significant therapeutic challenges due to high relapse rates and resistance to therapy.
Qiang Liu, Yanhua Wang, Yang Shi, Amit Verma, Qing Wang, Wei Cai, Wenjun Deng, Haiying Cheng, Rafi Kabarriti, Jianhong An, Erqiang Hu, Yanan Fang, Naijia Liu, Wu He, Angelina Wang, Yinghui Song, Jidong Shan, Jinghang Zhang, Yiyu Zou, Roberto Alejandro Sica, Shanye Yin   +20 more
doaj   +1 more source

Talimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma

, 2021
Talimogene laherparepvec (T-VEC) is an oncolytic virus (OV) therapy derived from the JS1 strain of herpes simplex virus one that was approved by the Food and Drug Administration in 2015 to be administered as direct injection therapy for patients with ...
Ollila, David W., Jenkins, Frances G., Johnson, Jeffrey E., Collichio, Frances   +3 more
core  

Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database

, 2020
Aim: There is a growing body of data on real-world use of talimogene laherparepvec (T-VEC). We aimed to characterize real-world T-VEC use using a nationally representative German prescription database covering 60% of prescriptions reimbursed.
Louie, Karly S, Banks, Victoria, Mohr, Peter, Öhrling, Katarina, Richter, Hartmut, Haferkamp, Sebastian, Scholz, Florian   +6 more
core   +1 more source

Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival. [PDF]

BACKGROUND: Talimogene laherparepvec (T-VEC) is an FDA-approved oncolytic herpesvirus therapy used for unresectable stage IIIB through IV metastatic melanoma.
Stitzenberg, Karyn B, Pham, P Veronica, Ologun, Gabriel O, Ismail, Sherin, Sorah, Jonathan D, Meyers, Michael O, Ollila, David W, Long, Patricia K, Landrum, Kelsey R, Jones, C Paige   +9 more
core   +1 more source

Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential

Frontiers in Microbiology
BackgroundHead and neck squamous cell carcinoma remains a significant global health burden, particularly in low-resource regions like India. Conventional treatments often fall short in achieving durable responses, prompting the need for novel therapies ...
Aditi Gupta, Samiran Ranjit Chavan, Ravisekhar Gadepalli, Puneet Pareek   +3 more
doaj   +1 more source

Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice.

PLoS ONE
Oncolytic viruses are a unique modality with multifaceted mechanisms of action for killing cancer cells and have been developed as a promising therapeutic approach in cancer treatment. The first-in-class agent, talimogene laherparepvec (T-VEC), has shown
Masahisa Hemmi, Midori Yamashita, Yoshiko Shimizu, Shinsuke Nakao   +3 more
doaj   +1 more source

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma. [PDF]

JAAD Case Rep, 2023
Beekman KE, Parker LM, DePalo DK, Elleson KM, Sarnaik AA, Tsai KY, Withycombe BM, Zager JS.   +7 more
europepmc   +1 more source

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient

JAAD Case Reports, 2021
Kelsey E. Hirotsu, MD, Vivian Hua, BA, Anhthy T. Tran, MSN, Laura Morris, BSN, Sunil A. Reddy, MD, Bernice Y. Kwong, MD, Lisa C. Zaba, MD, PhD   +6 more
doaj   +1 more source

Outcomes of Talimogene Laherparepvec in Soft Tissue Sarcoma. [PDF]

J Surg Oncol
Williams TP, Catalano S, Liebner DA, Grignol VP.   +3 more
europepmc   +1 more source

Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers. [PDF]

Ann Surg Oncol
Slatton J, Jiminez V, Beam J, Rademacher N, Montgomery K, Bateni S, Broman K.   +6 more
europepmc   +1 more source